Home › NDC Lookup › RxCUI directory › RxCUI 2697044

4 ML docetaxel 20 MG/ML Injection [Beizray] — RxCUI 2697044

Name: 4 ML docetaxel 20 MG/ML Injection [Beizray] (RxCUI 2697044)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2697044 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2697044

Official name4 ML docetaxel 20 MG/ML Injection [Beizray]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asBeizray 80 MG per 4 ML Injection; BEIZRAY 80 MG in 4 ML Injection

FDA products mapped6

Package NDCs mapped6

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Docetaxel Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It’s a chemotherapy medicine used for several cancers. Beizray is used for breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, stomach cance...
It’s given as an IV infusion at a medical facility, generally over about 1 hour every 3 weeks. You’ll take a steroid by mouth beforehand to help prevent fluid retention and allergi...
Common ones include low blood counts, infections, tiredness, nausea, diarrhea, mouth sores, hair loss, nail changes, numbness or tingling, and swelling. Your team will check your b...
Call for fever or signs of infection, trouble breathing or swelling during or after the infusion, severe diarrhea, severe skin reactions, worsening numbness or tingling, vision cha...

📖 Read our full Docetaxel Injection guide →

🕸️ Concept Web — How 4 ML docetaxel 20 MG/ML Injection [Beizray] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 4 ML docetaxel 20 MG/ML Injection [Beizray] RxCUI 2697044 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Docetaxel 72962 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Beizray 2697040 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Docetaxel Injection 1860479 SCDF
- Docetaxel Injectable Product 1160617 SCDG
- Docetaxel Injection [Beizray] 2697043 SBDF
- Beizray Injectable Product 2697042 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 4 ML docetaxel 20 MG/ML Injection 1860485 SCD
- Docetaxel 20 MG/ML 1001404 SCDC
- Docetaxel 20 MG/ML [Beizray] 2697041 SBDC
Packs 4

Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 15 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

4 ML docetaxel 20 MG/ML Injection SCD · 1860485
{1 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack GPCK · 2723663
{2 (4 ML docetaxel 20 MG/ML Injection) / 1 (50 ML albumin human-kjda 250 MG/ML Injection) } Pack GPCK · 2723665
Docetaxel 20 MG/ML SCDC · 1001404
Docetaxel Injection SCDF · 1860479
Docetaxel Injectable Product SCDG · 1160617

Brand-Name Concepts

{1 (4 ML docetaxel 20 MG/ML Injection [Beizray]) / 1 (50 ML albumin human-kjda 250 MG/ML Injection [Albuminex]) } Pack [Beizray 80 MG Kit] BPCK · 2723664
{2 (4 ML docetaxel 20 MG/ML Injection [Beizray]) / 1 (50 ML albumin human-kjda 250 MG/ML Injection [Albuminex]) } Pack [Beizray 160 MG Kit] BPCK · 2723666
Docetaxel 20 MG/ML [Beizray] SBDC · 2697041
Docetaxel Injection [Beizray] SBDF · 2697043
Beizray Injectable Product SBDG · 2697042
Beizray BN · 2697040

📦 FDA Products & Package NDCs

6 products · 6 package NDCs

6 package NDCs map to RxCUI 2697044 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
70710-2091-03	1 KIT in 1 KIT (70710-2091-3) * 4 mL in 1 VIAL, GLASS (707...	BEIZRAY	Zydus Pharmaceuticals USA Inc.	2025-08-28
70710-2092-08	1 VIAL, GLASS in 1 CARTON (70710-2092-8) / 1 mL in 1 VIAL,...	BEIZRAY	Zydus Pharmaceuticals USA Inc.	2025-12-15
70710-2093-04	1 KIT in 1 KIT (70710-2093-4) * 4 mL in 1 VIAL, GLASS (707...	BEIZRAY	Zydus Pharmaceuticals USA Inc.	2025-08-28
70710-2152-01	1 VIAL, GLASS in 1 CARTON (70710-2152-1) / 4 mL in 1 VIAL,...	BEIZRAY	Zydus Pharmaceuticals USA Inc.	2025-08-28
83513-0008-01	1 VIAL, GLASS in 1 CARTON (83513-008-01) / 1 mL in 1 VIAL,...	BEIZRAY	Zhuhai Beihai Biotech Co., Ltd.	2025-12-15
83513-0009-01	4 mL in 1 VIAL, GLASS (83513-009-01)	BEIZRAY	Zhuhai Beihai Biotech Co., Ltd.	2024-10-23

Observed labelers: Zydus Pharmaceuticals USA Inc. (4) · Zhuhai Beihai Biotech Co., Ltd. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J9174	Inj, docetaxel (beizray) 1mg	3	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.